Biocon gets DCGI nod for CytoSorb device to treat Covid-19 patients

CytoSorb therapy reduces cytokine storm and the inflammatory response in Covid-19 patients through blood purification so that injury to organs may be mitigated or prevented

Biocon’s subsidiary Biocon Biologics has received approval from the Drugs Controller General of India (DCGI) to use CytoSorb for treatment of Covid-19 patients. It is a device that reduces pro-inflammatory cytokine levels in Covid-19 patients admitted to the intensive care unit, with confirmed or imminent respiratory failure. 

A cytokine is a substance, such as interferon or interleukin, that is secreted by certain cells of the immune system and has an effect on other cells.

Biocon Biologics has been granted licence for emergency use of CytoSorb to treat Covid-19 patients aged 18 years or more. The licence will be effective until control of